TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Alaunos Therapeutics ( (TCRT) ) has shared an announcement.
On July 1, 2025, Dale Curtis Hogue, Jr. resigned from his roles as Chief Executive Officer and board member of Alaunos Therapeutics, Inc., transitioning to a consulting role with the company. His departure was not due to any disagreements, and he will continue to provide strategic and advisory services. On July 2, 2025, Holger Weis was appointed as the new CEO, bringing extensive experience from various roles in the life sciences and pharmaceutical industries. Weis will maintain his position as Chair of the Board but will step down from committee roles. His compensation includes a base salary and stock options, aligning with the company’s equity incentive plan.
Spark’s Take on TCRT Stock
According to Spark, TipRanks’ AI Analyst, TCRT is a Neutral.
Alaunos Therapeutics’ overall score is primarily impacted by its weak financial performance with ongoing losses and negative cash flows. While the technical analysis shows some positive momentum, the negative P/E ratio and lack of dividends underscore valuation challenges. The absence of earnings call and corporate events information further limits the stock’s appeal.
To see Spark’s full report on TCRT stock, click here.
More about Alaunos Therapeutics
Average Trading Volume: 195,787
Technical Sentiment Signal: Sell
Current Market Cap: $9.28M
For detailed information about TCRT stock, go to TipRanks’ Stock Analysis page.